Back  |
-
Subscribe to newsletter
 News
-
Get listed our directory
Pharmaceutical Research Centers
Jordan's Associations
Dental Laboratories
Nursing Centers
Medical Centers
Fitness Centers
Beauty Centers
Optic Centers
Drugstores
Hospitals
Doctors
Dentists
Dietitian
Companies
Pharmacies
Dental Centers
Herbal Centers
Scientific Offices
Infertility Centers
Dead Sea Factories
Medical Laboratories
Pharmaceutical Factories
FDA Approves First Pacemaker For Congestive Heart Failure

FDA today approved a new type of pacemaker that sends specially timed electrical impulses to the heart's lower chambers to treat the symptoms of moderate to severe congestive heart failure.
The device is the InSync Biventricular Cardiac Pacing System made by Medtronic, Inc., of Minneapolis.

The InSync system is the first pacemaker approved for treating the symptoms of congestive heart failure, a condition in which the heart can not adequately pump blood around the body. Standard pacemakers are used to treat rhythm disturbances in the heart, a different condition.

People with congestive heart failure typically experience fatigue and shortness of breath during exertion, and therefore have difficulty performing many of the routine tasks of daily living.

The InSync System consists of a pulse generator that is implanted in the chest and connected to the heart by three wires (leads) that deliver electrical impulses. One wire is placed in the upper right heart chamber and the others are placed in each of the two lower chambers, where they simultaneously stimulate both the left and right ventricles. This device differs from a standard pacemaker in that it has three leads instead of one or two leads.

FDA approved the product based on clinical studies of safety and effectiveness conducted by Medtronic and on the recommendation of the Circulatory System Devices Panel of FDA's Medical Devices Advisory Committee.

Medtronic studied use of the device in 579 patients with moderate to severe congestive heart failure at 44 medical centers in the U.S. and Canada. Patients were randomized to either having the pacemaker turned on or turned off and were followed for six months.

Overall, the majority of the patients in whom the pacemaker was turned on showed improvement in either quality of life scores, distance they were able to walk or their heart failure classification. Approximately one third of patients in the control group also saw improvement. There was no change in the mortality rates in the two groups.

The study did not reveal any major safety issues with the device itself; however, implanting the device requires special training on the part of the physician.

As part of the approval, Medtronic will be required to conduct a post-market evaluation of this device in 1,500 patients followed over three years.

Not all people with congestive heart failure have been shown to benefit from the new device. Patients who have not been helped by drug treatment and whose ventricles are not synchronized correctly are suitable candidates.  

Published on 23 November 2001
 
 
  Are You interested to promote your self @ Yemen, Bahrain, Sudan, Libya & Arbeel?
  Severe stress in pregnancy may affect fetal growth
  Weight loss may cut risk of colorectal growths
  Flu shot does not cut risk of death in elderly
  Low Levels of Brain Chemical May Control Appetite
  Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose
  Wearing an underwire bra increases your risk of getting breast cancer
  Businesswomen from Uganda and Ghana were second and third as Jordanian entrepreneur takes first prize at UNCTAD’s debut women in business awards
  Jordanian Woman Wins First Prize: Sana Burgan
  "Concept, Indication and Handling of the Friadent Implant System Xive" courses will be held in Jordan Soon

  Dr. Joudeh Operated on a big Tumor.....

  HealLand Newspaper
  HealLand Jordan Directory
  Happy Eid
  Are You Targeting Jordan, Yemen, Bahrain and All the Arabic World
  Afurnished Clinic 4 Rent..

  Med Grant Est. launched it's 2nd edition of HealLand Jordan book.

  On the occasion of The New Year, Johealth seize this......
  Watch Us Today 8th of Sep. On Jordan TV @ 5:40
  HealLand Jordan 2nd Edition
  During menopause, estrogen levels go down. At the same time, bone breakdown (resorption) may increase.
  A Star Sent From Heaven to Dr. Samer Sunna - A Girl

  Dr. Sana Hammouri the First and Only Jordanian Female General Surgeon in the private sector

  Dr. Disi, One of the pioneer Orthopeadics doctors in Jordan

  Sabarini Consultation & Training Est. Offers a lot of services

  For Sale.... Siemens Sonoline SX Sector Ultrasound Scanning Machine

  NEW YORK (Reuters Health) - Older people who exercise are less likely to be depressed,
  LabTechONE is now a client of mayo Medical Laboratories and will provide comprehensive laboratory services
  Chicco, the Italian firm as we all know, is one of the most famous brands world wide....
  JOHEALTH has moved !

  Rheumatoid Arthritis Treatment: The FDA has approved anakinra as adjunctive therapy for..
  FDA APPROVES NEW WEARABLE DEFIBRILLATOR
FOR SERIOUSLY ILL HEART PATIENTS.....
  Breast Tissue Ablation Device: The FDA has approved Cryocare Surgical System....
  Drug for Severe Adult Sepsis: The FDA has approved drotrecogin alfa (activated)...
  On the occasion of Ramadan, Johealth seize this......

  Dr. Najib Layyous, One of the most pioner doctors in Jordan specialized in Infertility...
  Under the unprecedented support of his Royal Majesty King Abdullah II, to further promote the use of internet services for the benefit of the Jordanian people
  A Jordanian Pediatrician invents the first Natural Anti Diarrhea Medication for babies, children and adults.
  FDA issues nationwide alert on the recall of "PIERRE FABRE physicians formula eye makeup remover lotion" because of health risk.
  FDA Approves First Pacemaker For Congestive Heart Failure
  FDA updates safety information for MICONAZOLE VAGINAL cream and suppositories
Copyright © 2000-2018 JoHealth. All rights reserved
info@johealth.com

Powered by Softimpact